KW-2149 (7-N-[2-[Y-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum

Biochemical Pharmacology

Volumn 53, Issue 3, 1997, Pages 279-285

  Masters, John R W ^a   Know, Richard J ^b   Hartley, John A ^c   Kelland, Lloyd R ^b   Hendriks, Hans R ^d   Connors, Tom ^e  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

bladder cancer; drug metabolism; intravesical chemotherapy; mitomycin C; new anticancer agent; serum factor

Indexed keywords

7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; ANTINEOPLASTIC AGENT; GLUTATHIONE; MITOMYCIN C; MITOMYCIN C DERIVATIVE; RADIOISOTOPE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA BINDING; DRUG BINDING; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM FACTOR; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BLOOD; DNA ADDUCTS; HUMANS; MICE; MITOMYCIN; MITOMYCINS; TUMOR CELLS, CULTURED;

EID: 0031041221     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00687-9     Document Type: Article

References (13)

1. Kono M, Saitoh Y, Kasai M, Sato A, Shirahata K, Morimoto M and Ashizawa T, Synthesis and antitumor activity of 7-N-{{2-{[Y-L-glutamylamino)ethyl]dithio}ethyl}}mitomycin C. Chem Pharm Bull 37: 1128-1130, 1989.
2. Dirix L, Catimel G, Koier I, Prove A, Schrijvers D, Joossens E, de Bruijn E, Ardiet C, Evene E, Dumortier A, Clavel M and van Oosterom A, Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. Anti-Cancer Drugs 6: 53-63, 1995.
3. Ashizawa T, Okabe M, Gomi K and Hirata T, Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice. Anti-Cancer Drugs 4: 181-188, 1993.
4. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M and Saijo N, In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, Menogaril, and Liblomycin using cisplatin-or adriamycin-resistant human cancer cell lines. Cancer Res 49: 4098-4102, 1989.
5. Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y, Arai H, Sato A, Kasai M and Tsuruo T, Antitumor activity of 7-N-{{2-{[2(Y-Glutamylamino)ethyl]dithio}ethyl}}mitomycin-C. Cancer Res 51: 110-115, 1991.
6. Tsuruo T, Sudo Y, Asami N, Inaba M and Morimoto M, Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(Y-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against human tumors and a mitomycin-C resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol 27: 89-93, 1990.
7. Dirix L, Gheuens EEO, van der Heyden S, van Oosterom AT and De Bruijn EA, Cytotoxic activity of 7-N-(2-((2-(-Y-L-glutamylamino)-ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns. Anti-Cancer Drugs 5: 343-354, 1994.
8. Masters JRW, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR and Franks LM, Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 6: 3630-3636, 1986.
9. Kobayashi S, Ushiki J, Takai K, Okumura S, Kono M, Kasai M, Gomi K, Morimoto M, Ueno H and Hirata T, Disposition and metabolism of KW-2149, a novel anticancer agent. Cancer Chemother Pharmacol 32: 143-150, 1993.
10. Roberts JJ and Friedlos F, The frequency of interstrand crosslinks in DNA following reaction of cis-diammine-dichloroplatinum(II) with cells in culture or DNA in vitro: stability of DNA cross-links and their repair. Chem-Biol Interactions 39: 181-189, 1982.
11. Kobayashi E, Okabe M, Kono M, Arai H, Kasai M, Gomi K, Lee J-H, Inaba M and Tsuruo T, Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C. Cancer Chemother Pharmacol 32: 20-24, 1993.
12. Lee J-H, Naito M and Tsuruo T, Nonenzymatic reductive activtion of 7-N-{{2-{[2-(Y-L-glutamylamino)ethyl]dithio}-ethyl}}-mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res 54: 2398-2403, 1994.
13. He Q-Y, Maruenda H and Tomasz M, Novel bioreductive activation mechanism of mitomycin C derivatives bearing a disulfide substituent in their quinone. J Am Chem Soc 116: 9349-9350, 1994.